A patient with von Willebrand factor (vWF) deficiency bleeds for a long time from minor cuts, but large wounds eventually stop bleeding (slowly) with normal fibrin formation. What does this pattern reveal about hemostasis?
BvWF is required for platelet adhesion in primary hemostasis; its absence impairs the platelet plug, but the coagulation cascade can still generate fibrin — demonstrating that primary and secondary hemostasis are partially independent systems
CThe pattern indicates a concurrent factor XII deficiency that slows but doesn't abolish clotting
DNormal fibrin formation is impossible without vWF because vWF directly activates thrombin
vWF tethers platelets to exposed subendothelial collagen via the GPIb receptor, initiating primary hemostasis. Without it, the platelet plug forms poorly or not at all, causing prolonged bleeding from minor injuries. However, the coagulation cascade (secondary hemostasis) can still be triggered by tissue factor via the extrinsic pathway and ultimately generate fibrin — explaining why larger wounds eventually seal. This dissociation between primary and secondary hemostasis is the diagnostic signature of vWF disease.
Question 2 Multiple Choice
Why does the coagulation cascade generate thrombin so effectively from a tiny initial tissue factor signal?
AThrombin is stored in platelets at high concentration and released immediately upon activation
BEach step activates the next serine protease in a sequential cascade, so a few active molecules at the start generate exponentially increasing numbers of downstream molecules, culminating in massive thrombin production
CPlatelets directly synthesize thrombin from fibrinogen once aggregated
DTissue factor continuously regenerates throughout the clotting process, sustaining thrombin output
The cascade is fundamentally a signal amplification system. A small number of active factor VIIa–tissue factor complexes activate factor X; each factor Xa molecule activates many molecules of prothrombin to thrombin; thrombin itself feeds back to activate factors V and VIII, accelerating its own production further. This enzymatic amplification — where each active protease processes many substrate molecules — converts a tiny injury signal into the large thrombin burst needed to rapidly polymerize fibrin across a wound.
Question 3 True / False
The platelet plug formed during primary hemostasis is a fragile, temporary structure — significant vessel injuries require fibrin reinforcement from the coagulation cascade to form a stable, durable clot.
TTrue
FFalse
Answer: True
The platelet plug — platelets adhered and aggregated via fibrinogen bridges between GPIIb/IIIa receptors — is sufficient for minor injuries like small capillary breaks, but it is mechanically unstable and cannot withstand arterial or venous pressure in larger injuries. Secondary hemostasis reinforces it with cross-linked fibrin strands (stabilized by factor XIII), creating the tough meshwork that anchors platelets and withstands circulatory forces. The two phases are complementary: primary hemostasis acts within seconds; secondary hemostasis consolidates within minutes.
Question 4 True / False
Once activated, the coagulation cascade propagates throughout the bloodstream until most circulating fibrinogen is consumed; the body relies on clot formation being fast enough to seal the injury before this runaway process occurs.
TTrue
FFalse
Answer: False
Multiple anticoagulant mechanisms confine clotting precisely to the injury site. Antithrombin III continuously inactivates thrombin and factor Xa in free solution. Protein C — activated by thrombomodulin on intact endothelium away from the wound — degrades factors Va and VIIIa. Tissue factor pathway inhibitor (TFPI) rapidly shuts down the extrinsic trigger. Together these ensure that coagulation is self-limiting spatially and temporally. Fibrinolysis (plasmin-mediated fibrin degradation) then dissolves the clot once repair begins. Without these brakes, trivial injuries would cause fatal systemic thrombosis.
Question 5 Short Answer
Why is the balance between clotting and anticoagulation clinically critical, and what happens when it is disrupted in either direction?
Think about your answer, then reveal below.
Model answer: Hemostasis must be precisely balanced: sufficient clotting to seal injury, but strictly confined so it doesn't propagate pathologically. Tipping toward excessive clotting produces thrombosis — inappropriate clots can occlude vessels, causing stroke (cerebral artery), pulmonary embolism (pulmonary artery), or deep vein thrombosis. Tipping toward insufficient clotting causes hemorrhage — inability to seal even minor wounds, as seen in hemophilia (factor VIII/IX deficiency) or thrombocytopenia. This balance is the pharmacological target of most coagulation drugs: anticoagulants (warfarin inhibits vitamin K-dependent factors; heparin potentiates antithrombin III; direct oral anticoagulants block thrombin or factor Xa) reduce clot risk in high-risk patients, while thrombolytics (tPA) activate plasmin to dissolve pathological clots after ischemic stroke.
The key insight is that hemostasis is not just about 'clotting fast' — it requires active, redundant mechanisms to limit clotting both spatially (to the injury site) and temporally (until healing is complete). Clinical disease arises from failure of either the pro-clotting or anti-clotting arms.